![Welcome sign in Libby, Montana](https://www.asbestos.com/wp-content/uploads/Libby-Sign-480x320-c-default.jpg)
The Mesothelioma Center News – Page 23
-
newsAsbestos Exposure & BansThe Center for Asbestos Related Disease in Libby, Montana, dodged a potential setback recently when officials from the U.S. Department of Justice decided against…
-
newsLegislation & Litigation
Johnson & Johnson Preparing $3.9 Billion for Talc Settlements
Pharmaceutical giant Johnson & Johnson has set aside $3.9 billion for talc-related litigation, according to a regulatory filing this week with the Securities and… -
newsResearch & Clinical Trials
Study: Which Mesothelioma Patients Will Immunotherapy Benefit?
Thoracic surgeon Dr. Bryan Burt at the Baylor College of Medicine wants to better identify which patients with pleural mesothelioma cancer will benefit (and… -
newsTreatment & Doctors
Winter Storm Delays Cancer Treatment Across U.S.
Severe winter storms have affected multiple central U.S. states with power outages and water supply disruptions. State officials in Texas, Louisiana and Mississippi say… -
newsResearch & Clinical Trials
FDA Fast-Tracks Mesothelioma Vaccine Development
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. -
newsResearch & Clinical Trials
Research Reinforces Gene Mutation Links to Mesothelioma
More than ever, Dr. Michele Carbone at the University of Hawaii Cancer Center believes early testing for genetic mutations can lead to fewer cases… -
newsAsbestos Exposure & Bans
Mesothelioma Still Prevalent in Canada Following Asbestos Ban
More than two years after implementing a much-celebrated ban of asbestos, Canadians have come to realize the real fight has only just begun. Malignant … -
newsResearch & Clinical Trials
Opdivo Study Offers Hope to Relapsed Mesothelioma Patients
A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and… -
newsLegislation & Litigation
EPA’s Asbestos Risk Evaluation Faces Litigation
The Asbestos Disease Awareness Organization continued its challenge of the U.S. Environmental Protection Agency, filing a petition for review Jan. 26 in… -
newsResearch & Clinical Trials
Study: Mesothelioma Survival Rates Rise with SMART Protocol
Using accelerated high-dose radiation prior to surgery produced an unprecedented 65.9-month median survival for a cohort of pleural mesothelioma patients who were part of a…